Omeros Corporation (OMER) Stock Analysis

Omeros Corporation (OMER) is a publicly traded company in the HEALTHCARE sector. It trades at $10.26, carries a market capitalization of $775.86M, a price-to-earnings ratio of 9.40. This page summarizes the public market data, fundamentals, and frequently asked questions for OMER, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $10.26
• Market Cap: $775.86M
• P/E Ratio: 9.40
• EPS: $1.14
• 52-Week High: $17.65
• 52-Week Low: $2.95

Market Sentiment

Omeros Corporation currently has a Neutral sentiment score of -0.01.

About Omeros Corporation

Omeros Corporation is a Seattle-based biopharmaceutical firm that specializes in the discovery, development, and commercialization of novel therapeutics aimed at serious conditions. The company boasts a diverse pipeline featuring both protein and small molecule therapies, targeting critical unmet medical needs in areas such as inflammation, complement-mediated diseases, and central nervous system (CNS) disorders. With a strategic focus on orphan indications, Omeros is well-equipped to drive g...

GNG Research Analysis

GNG Research scores Omeros Corporation (OMER) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for OMER.

Frequently Asked Questions

Does OMER pay dividends?

Omeros Corporation (OMER) does not currently pay a regular dividend.

What is OMER's P/E ratio?

Omeros Corporation has a price-to-earnings (P/E) ratio of 9.40.

What is OMER's market cap?

Omeros Corporation (OMER) has a market capitalization of $775.86M with a current stock price of $10.26.